Magee-Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA 15213;
Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.
Estrogen receptor (ER) level can be semiquantified by immunohistochemistry (IHC) using the H-score. The score, given as the sum of the percent staining multiplied by the intensity level, ranges from 0 to 300.
Forty-nine ER+/HER2- invasive tumors with low ER expression (H-scores of 1-100, representing approximately 5% of all tumors) were studied for various morphologic parameters, progesterone receptor (PR), and Ki-67 IHC.
Eighteen of 49 patients received neoadjuvant chemotherapy. The morphologic analysis showed that these tumors are often grade 3 and frequently demonstrate a sheet-like growth pattern, an intratumoral lymphocytic inflammatory infiltrate, and necrosis. Eighty percent of tumors showed a Ki-67 proliferation index of more than 50%, and 94% were PR-. Of the 18 patients who received neoadjuvant chemotherapy, six (33%) achieved pathologic complete response.
The low ER+/HER2- cases have morphologic features and a response to the chemotherapy rate that are more similar to triple-negative tumors than the usual type of ER+ tumors.
雌激素受体 (ER) 水平可通过免疫组织化学 (IHC) 使用 H 评分进行半定量。该评分是染色百分比乘以强度级别的总和，范围从 0 到 300。
研究了 49 例 ER+/HER2-浸润性低 ER 表达肿瘤 (H 评分 1-100，约占所有肿瘤的 5%)，对其进行了各种形态学参数、孕激素受体 (PR) 和 Ki-67 IHC 分析。
18 例患者接受了新辅助化疗。形态学分析显示，这些肿瘤通常为 3 级，常表现为片状生长模式、肿瘤内淋巴细胞炎症浸润和坏死。80%的肿瘤 Ki-67 增殖指数>50%，94%的肿瘤 PR-。在接受新辅助化疗的 18 例患者中，有 6 例 (33%)达到了病理完全缓解。
低 ER+/HER2-病例的形态特征和对化疗的反应与三阴性肿瘤更相似，而不是通常的 ER+肿瘤。
